Vanguard Group Inc Akebia Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKBA
# of Institutions
127Shares Held
56.7MCall Options Held
937KPut Options Held
743K-
Satter Management Co., L.P.13.2MShares$12.7 Million26.98% of portfolio
-
Acadian Asset Management LLC Boston, MA5.31MShares$5.1 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.65MShares$3.51 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$3.14 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.54MShares$2.44 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $176M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...